Thymosin Alpha-1 10mg Peptide

Chemical diagram for Thymosin Alpha-1 by Meodipt (talk) – Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=180743089

KEY SPECIFICATIONS

PRODUCT OVERVIEW

Thymosin Alpha-1 (Ta1) is a synthetic 28-amino-acid peptide analog of the naturally occurring thymic hormone. The N-terminal acetylation provides enhanced stability against aminopeptidase degradation. Research demonstrates modulation of Toll-like receptor signaling (TLR2, TLR9), dendritic cell maturation, and T-lymphocyte differentiation. Studies document effects on MHC Class II upregulation, CD4+/CD8+ ratio restoration (MD=4.53 and MD=0.42 in 2025 meta-analysis), and enhanced NK cell cytotoxicity. 2024-2025 research demonstrates synergistic effects with PD-1/PD-L1 checkpoint inhibitors. With approval in 35+ countries and extensive clinical investigation history, Ta1 is among the most studied immunomodulatory peptides available. BIONIX supplies Ta1 with ≥99% purity for immunological research applications.

MECHANISM OF ACTION

Thymosin Alpha-1 operates through multiple interconnected immunological pathways, enhancing both innate and adaptive immune responses in experimental systems.

TLR Signaling Pathways:

Dendritic Cell and T-Cell Mechanisms:

N-Terminal Acetylation Stability:

Proposed Signaling Pathway:

Thymosin Alpha-1 → TLR2/TLR9 Binding → MyD88-Dependent Pathway → 
NF-κB/AP-1 Activation → Dendritic Cell Maturation → T-Cell Activation → 
Th1 Cytokine Release (IFN-γ, IL-2, IL-12) + NK Enhancement

Comparative Profile:

RESEARCH APPLICATIONS

• Immunomodulation and Cytokine Research: Th1/Th2 cytokine balance studies analyzing IFN-γ, IL-2, and IL-12 production. Antigen presentation assays, co-stimulation studies, and vaccine adjuvant development. Phase 1 clinical trial (NCT06821100) currently investigating Ta1 as COVID-19 vaccine enhancer for immunogenicity evaluation.

• Oncology and Checkpoint Inhibitor Synergy: Antiproliferative activity in tumor cell lines, cell cycle arrest (G0/G1 phase), apoptosis induction, and MHC Class I upregulation. 2024-2025 studies demonstrate synergistic effects with PD-1/PD-L1 inhibitors—tripled response rates in melanoma lung metastasis models when combined with dacarbazine. NSCLC research shows improved survival with concurrent chemoradiotherapy and consolidative immunotherapy.

• Severe Acute Pancreatitis Models: 2025 meta-analysis of 5 RCTs (n=706) demonstrated increased CD4+ T-cell populations (MD=4.53), improved CD4+/CD8+ ratios (MD=0.42), reduced inflammatory markers, and infection prevention. Establishes Ta1 as valuable tool for investigating immune dysregulation in acute inflammatory conditions.

• Neuroimmune Interaction Studies: Preclinical mouse models correlating systemic immunomodulation with BDNF hippocampal expression, doublecortin neuronal plasticity markers, bidirectional immune-CNS communication, and cognitive performance in spatial learning paradigms.

• Hepatitis and Viral Infection Models: Research history in hepatitis B and C models documenting enhanced viral clearance in combination protocols, improved immune reconstitution, and reduced inflammatory liver damage markers.

• Dendritic Cell Activation Research: TLR-dependent dendritic cell maturation studies in antifungal and infectious disease models, investigating Th1 polarization mechanisms and enhanced antigen presentation capacity.

ANALYTICAL VERIFICATION

BIONIX Thymosin Alpha-1 undergoes comprehensive analytical characterization:

• HPLC Analysis: Reversed-phase chromatography with gradient separation and UV detection at 214 nm confirms ≥99% purity; separates target peptide from impurities, byproducts, and degradation products • Mass Spectrometry: ESI-MS for precise molecular weight (3108.3 g/mol); MS/MS verifies amino acid sequence through fragmentation analysis • Water Content: Karl Fischer titration determination • Amino Acid Analysis: Peptide content verification • Endotoxin Testing: LAL assay for cell culture applications • Microbiological Testing: Sterility assurance protocols

Physical Characteristics:

DEVELOPMENT STATUS

• Research History: Extensive clinical investigation in hepatitis, oncology, and critical care; over 50 peer-reviewed publications • Clinical Applications: Approved as Zadaxin/Thymalfasin in 35+ countries (China, Southeast Asia, South America, Europe) for hepatitis treatment and cancer immunotherapy adjuvant use; 30+ years clinical use • United States: Not FDA-approved; Orphan Drug designation for hepatocellular carcinoma and malignant melanoma • European Union: Available exclusively for laboratory research • Current Trials: PD-1/PD-L1 checkpoint inhibitor synergy studies, vaccine adjuvant applications (NCT06821100), critical care immunomodulation • Recent Evidence: 2025 severe acute pancreatitis meta-analysis; 2024-2025 oncology combination studies • WADA Status: Research compound (verify current prohibited list)

BIONIX Thymosin Alpha-1 is supplied exclusively for laboratory research purposes—not for therapeutic use, human administration, veterinary, or clinical applications in non-approved jurisdictions.

FREQUENTLY ENCOUNTERED INQUIRIES

What is Thymosin Alpha-1 and how does it work?

Thymosin Alpha-1 is a synthetic 28-amino-acid peptide analog of the naturally occurring thymic hormone with N-terminal acetylation for enhanced stability. Research demonstrates modulation of immune signals through Toll-like receptor (TLR2, TLR9) pathways, MyD88-dependent NF-κB/AP-1 activation, MAPK signaling, and dendritic cell maturation. Mechanisms include MHC Class II and CD80/CD86 upregulation, CD4+ T-cell expansion, and Th1 cytokine enhancement (IFN-γ, IL-2).

What is the difference between Thymosin Alpha-1 and Thymosin Beta-4?

Distinct peptides with different mechanisms and research applications. Thymosin Alpha-1 (28 amino acids) targets TLR pathways and T-cell enhancement for immunomodulation and oncology research with N-acetylation stability. Thymosin Beta-4 (43 amino acids) focuses on actin sequestration and tissue repair/regeneration. Ta1 is approved in 35+ countries for clinical immunotherapy; TB4 remains in research phases.

What purity does BIONIX Thymosin Alpha-1 have?

Each batch is HPLC-verified for ≥99% purity with mass spectrometry confirming molecular identity (3108.3 g/mol) and amino acid sequence integrity. Batch-specific Certificates of Analysis document all quality parameters including HPLC chromatograms, mass spectra, purity assessments, and are available with every shipment.

What storage conditions are required?

Lyophilized powder requires -20°C storage for long-term stability (up to 24 months). Protect from moisture and light. Post-reconstitution, store at 2-8°C for 7-10 days or aliquot and freeze at -20°C (1-3 months) or -80°C (6-12 months). Avoid repeated freeze-thaw cycles and allow vial to equilibrate to room temperature before opening.

Is Thymosin Alpha-1 approved for clinical use?

Ta1 (marketed as Zadaxin/Thymalfasin) is approved in over 35 countries for hepatitis treatment and cancer immunotherapy adjuvant use with 30+ years clinical history. It is not FDA-approved in the United States (Orphan Drug designation only) and is available in the EU exclusively for laboratory research. BIONIX supplies research-grade material for laboratory use only—not for human therapeutic application.

How is Thymosin Alpha-1 reconstituted?

Reconstitute in sterile water, PBS, or appropriate buffer based on experimental requirements. Gently swirl until fully dissolved—avoid vortexing to prevent aggregation and structural damage. Select concentration based on experimental design and aliquot immediately into single-use portions. Maintain aseptic conditions throughout reconstitution and storage.

REFERENCES

• PMID: PMC12640775 — Thymosin α1 elevates lymphocyte counts in advanced cancer (2025)
• Transl Lung Cancer Res, 2025 — Long-term thymosin α1 integration with chemoradiotherapy in LA-NSCLC
• Front Immunol, 2025 — Thymosin alpha 1 in severe acute pancreatitis: Meta-analysis (5 RCTs, n=706)
• NCT06821100 — Thymalfasin as Vaccine Enhancer (COVID-19 Phase 1), 2025
• Cancer Manag Res, 2025 — Thymosin α1 combined with PD-1/PD-L1 inhibitor plus chemotherapy
• Preclinical Data — TLR-dependent dendritic cell activation in antifungal models
• Approved Product — Zadaxin/Thymalfasin (35+ country regulatory approvals)